CAJ | 학술논문

目的：分析血清总胆红素联合溶血三项试验在新生儿溶血病早期诊治中的应用价值。方法以我院2013年1—12月收治的100例新生儿（母亲血型均为O型）为研究对象，均表现为高胆红素血症，对其行溶血三项试验（抗体放散试验、直接抗人球蛋白试验及游离抗体试验），根据试验阳性率分为四组，对所有患儿经蓝光光疗、丙种球蛋白静脉注射等治疗，通过全自动生化分析仪测定比较各组治疗前后血清总胆红素水平。结果100例新生儿中，A组16例，B组6例，C组49例，D组29例。四组患儿治疗后血清总胆红素较治疗前明显下降，差异有统计学意义（P＜0．05）。治疗前四组患儿血清总胆红素水平：A组＞C组＞B组＞D组，组间比较差异无统计学意义（P＞0．05）。结论溶血三项试验联合血清总胆红素检测有利于新生儿溶血病早期诊断、治疗。
목적：분석혈청총담홍소연합용혈삼항시험재신생인용혈병조기진치중적응용개치。방법이아원2013년1—12월수치적100례신생인（모친혈형균위O형）위연구대상，균표현위고담홍소혈증，대기행용혈삼항시험（항체방산시험、직접항인구단백시험급유리항체시험），근거시험양성솔분위사조，대소유환인경람광광료、병충구단백정맥주사등치료，통과전자동생화분석의측정비교각조치료전후혈청총담홍소수평。결과100례신생인중，A조16례，B조6례，C조49례，D조29례。사조환인치료후혈청총담홍소교치료전명현하강，차이유통계학의의（P＜0．05）。치료전사조환인혈청총담홍소수평：A조＞C조＞B조＞D조，조간비교차이무통계학의의（P＞0．05）。결론용혈삼항시험연합혈청총담홍소검측유리우신생인용혈병조기진단、치료。
Objective To analyze the application value of detecting serum total bilirubin combined with hemolysis test in diagnosing hemolytic disease of the newborn.Methods 100 cases of newborn ( whose mother's blood type were O ) treated in our hospital during January 2013 and December 2013 were chose as research object, all of them with the disease of hyperbilirubinemia, and all of them received three hemolysis experiments ( antibody elution test, direct anti -globulin test and free antibody test ) .They were divided into four groups according to the positive rate.The patients underwent blue light phototherapy, intravenous immunoglobulin treatment.Total bilirubin level in serum was detected by automatic biochemical analyzed instrument.Results Among the 100 cases of newborns, 16 cases in group A, 6 cases in group B, 49 cases in group C, 29 cases in group D.The total bilirubin in serum of four groups after treatment were significantly decreased than that before treatment, the differences were statistically significant (P<0.05).Total bilirubin levels in serum of four groups before treatment decreased as the range:group A, group C, group B and group D, the differences among the groups had no significant (P>0.05).Conclusions The combination detection of total bilirubin in serum and hemolytic three test is conducive to early diagnosis, treatment of hemolytic disease of the newborn.